Effects of octreotide on serum insulin-like growth factor I and insulin-like growth factor binding proteins in patients with cirrhosis

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 62, Issue 1, 2002, Pages 39-47

  Ottesen, Lone Harild ^a   Frystyk, J ^a   Kiszka Kanowitz, M ^a   Gronbaek H ^a   Bendtsen, F ^a   Flyvbjerg, A ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

C peptide; Free IGF I; GH IGF I axis; Growth hormone; IGFBP 3; Insulin, IGFBP 1

Indexed keywords

C PEPTIDE; GLUCOSE; GROWTH HORMONE; INSULIN; OCTREOTIDE; PLACEBO; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; IMMUNOASSAY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; WESTERN BLOTTING;

TRIXIS;

EID: 0036185537     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655102753517190     Document Type: Article

References (41)

1. Liver disease, carbohydrate metabolism and diabetes
2. Prognostic significance of diabetes in patients with cirrhosis
3. Regulation of somatomedin-C/insulin-like growth factor I by nutrients
4. Nutrition and somatomedin. XXII: Molecular regulation of insulin-like growth factor-I during fasting and refeeding in rats
5. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously
6. The insulin-like growth factors and their binding proteins
7. Molecular regulation of insulin-like growth factor-I and its principal binding protein, IGFBP-3
8. Identification of an insulin-responsive element in the promoter of the human gene for insulin-like growth factor binding protein I
9. Reduced serum somatomedin activity in patients with chronic liver disease
10. Circulating growth hormone and insulin-like growth factor-I in nonalcoholic liver cirrhosis with or without superimposed hepatocarcinoma: Evidence of an altered circadian rhythm
11. Insulin-like growth factor I: A good indicator of functional hepatocellular capacity in alcoholic liver cirrhosis
12. Urinary growth hormone (U-GH) excretion and serum insulin-like growth factor I (IGF-1) in patients with alcoholic cirrhosis
13. Growth hormone, insulin-like growth factor-1, and insulin-like growth factor binding proteins 1 and 3 in chronic liver disease
14. Insulin-like growth factor-I serum concentrations and patterns of insulin-like growth factor binding proteins in patients with chronic liver disease
15. Sclerotherapy with or without octreotide for acute variceal bleeding
16. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation
17. Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial
18. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995
19. Relationship between somatomedin-C and growth hormone levels in acromegaly: Basal and dynamic evaluation
20. Transection of the oesophagus for bleeding oesophageal varices
21. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II
22. Free insulin-like growth factors (IGF-I and IGF-II) in human serum
23. Analysis of serum insulin-like growth factor binding proteins using Western blotting: Use of the method for titration of the binding proteins and competitive binding studies
24. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
25. Analysis of serial measurements in medical research
26. Somatomedin production in normal adults and cirrhotic patients
27. Concentrations, release and disposal of insulin-like growth factor (IGF)-binding proteins (IGFBPs), IGF-I and growth hormone in different vascular beds in patients with cirrhosis
28. IGF-I and GH: Metabolic effects during experimentally induced catabolism
29. Insulin-like growth factor-I improves glucose metabolism and hepatic amino acid-n conversion in patients with liver cirrhosis
30. Somatostatin and octreotide in the management of acute variceal hemorrhage
31. Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: A randomized, double-blind, controlled trial
32. The insulin-like growth factor binding protein 3 ternary complex is reduced in cirrhosis
33. Effect of octreotide on circulating IGF-I chromatographic profile: Evidence for an inhibitory action on the formation of the 150-kDa ternary complex
34. Direct effects of somatostatin analog octreotide on insulin-like growth factor-I in the arterial wall
35. Insulin-like growth factor-binding protein-1 modulates blood glucose levels
36. Somatostatin-stimulated insulin-like growth factor binding protein-1 release is abolished by hyperinsulinemia
37. Octreotide stimulates insulin-like growth factor binding protein 1 (IGFBP-1) levels in acromegaly
38. Octreotide stimulates insulin-like growth factor-binding protein-1: A potential pituitary-independent mechanism for drug action
39. Stimulation of hepatic insulin-like growth factor-binding protein-1 and -3 gene expression by octreotide in rats
40. Cirrhotic liver expresses low levels of the full-length and truncated growth hormone receptors
41. Determination of the hepatic galactose elimination capacity after a single intravenous injection in man. The reproducibility and the influence of uneven distribution